Jenoptik

Jenoptik is the most successful spinoff from the former East German Carl Zeiss Jena state combine. Headquartered in Jena, Thuringia, the company has 4,020 employees and a 2.55B EUR market cap. Jenoptik operates four segments: Semiconductor & Advanced Manufacturing (precision optics for ASML lithography systems), Biophotonics (medical optics), Metrology & Production Solutions (measurement systems), and Smart Mobility Solutions (traffic-safety and infrastructure monitoring).

The 2025 derating from 46 EUR peak to a 16 EUR low was driven by automotive softness in the Mobility segment plus a delayed ramp at one ASML EUV customer. Both have inflected in 2026. ASML 2026 capex guide of 25B EUR plus the new High-NA EUV ramp at TSMC and Intel translates directly into precision-optics demand for Jenoptik. The Mobility segment recovered with new infrastructure-monitoring contracts in Germany, Netherlands, and the US.

By May 2026 the stock has recovered to 44.50 EUR — still well below the 46 EUR peak but showing meaningful trajectory recovery. The 2026 forward P/E of 20x reflects re-acceleration optimism without yet fully pricing in the ASML High-NA ramp through 2028 and the German defense-budget tailwind on the Smart Mobility segment.

The largest single holder is the Federal State of Thuringia via Thuringer Industriebeteiligungsgesellschaft, holding approximately 10.4% — a public-sector strategic block that provides stability and an implicit floor under takeover speculation. Thuringia has held this stake since the 1996 IPO and has never reduced.

Among external institutional holders, Allianz Global Investors (3.5%) and Norges Bank Investment Management (3.1%) are largest. The notable 2025 entry was Lyrical Asset Management at 3% in Q4 — a US value specialist with strong track record in European industrial spinoffs. Their entry signals a recognition of the cycle-bottom optionality plus ASML supply-chain advantage.

Insider activity in 2025-2026 has been minimal. CEO Stefan Traeger has not transacted in 2026. CFO Daniel Heid made a small open-market purchase of 4,200 shares at 28 EUR in October 2025. No major officer or director sells in the past 18 months. The dividend was raised 4% for fiscal 2025 despite weak earnings — a moderate confidence signal.

Jenoptik trades at a forward P/E of 20x on 2026 consensus EPS of 2.20 EUR, against the European specialty-photonics peer median of 19x. The slight premium reflects the ASML-leveraged growth story and Biophotonics compounding. EV/EBITDA at 11x is in line with Carl Zeiss Meditec at 14x and TKH Group at 9x. Sell-side targets range from 36 EUR (Berenberg, bear case at slowing ASML capex) to 62 EUR (Hauck Aufhäuser, bull case at full High-NA ramp plus defense-budget acceleration). Fair value at 52-56 EUR implies 17-26% upside from current 44.50 EUR. The 0.9% dividend yield is supportive but not a thesis driver.

1. August 2026: H1 2026 results — first half reflecting ASML High-NA ramp visibility and German defense contract wins
2. Q4 2026: ASML 2027 capex guidance plus TSMC/Intel High-NA installation milestones — direct lever on Semiconductor segment 2027-2028 revenue trajectory
3. Q1 2028: Full High-NA EUV system installed base milestone — Jenoptik Semiconductor segment revenue at peak cycle visibility

Jenoptik is the cleanest European mid-cap leverage play on the ASML High-NA EUV cycle. The Thuringia 10.4% public-sector block is a stability anchor that prevents the kind of downside acceleration we saw in 2025. The Biophotonics compounding is the structural growth story; ASML is the cycle catalyst; German defense budget is the optionality kicker. I size JEN.DE at 1-2% as a 2-3 year specialty-photonics play with target 55-60 EUR. If ASML capex disappoints or High-NA delays push to 2029, this could revisit 30 EUR — sizing accordingly.